Physician profile
Mark S Mlcak
NPI 1699797936
$1,249.64
in general payments reported to CMS, 2019-2025
20 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $959 · 2020: $136 · 2021: $140 · 2022: $14.04.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $239.33 | 2019-2020 | |
| Novo Nordisk INC | $193.30 | 2019-2021 | |
| Amarin Pharma, INC. | $146.91 | 2019-2021 | |
| Astellas Pharma US INC | $95.81 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.19 | 2019-2020 | |
| Pfizer INC. | $70.05 | 2019-2020 | |
| Glaxosmithkline, LLC. | $67.54 | 2019-2021 | |
| Genentech USA, INC. | $48.87 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $41.08 | 2019 | |
| Abbott Laboratories | $37.41 | 2019 | |
| Merck Sharp & Dohme LLC | $36.36 | 2019 | |
| Biohaven Pharmaceuticals, INC. | $32.74 | 2021 | |
| Amgen INC. | $29.99 | 2019 | |
| Sanofi Pasteur INC. | $28.28 | 2019 | |
| Lilly USA, LLC | $25.86 | 2019-2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $25.83 | 2019 | |
| Abbvie INC. | $14.04 | 2022 | |
| Eisai INC. | $13.65 | 2021 | |
| Optinose US, INC. | $11.52 | 2019 | |
| Dynavax Technologies Corporation | $9.88 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Mlcak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.